There may be an option for hypoparathyroidism that leaves room for the toothpaste.

We invite people 18 years of age and older with hypoparathyroidism to see if they may qualify for the PARALLAX Study. The purpose of the PARALLAX Study is to measure the safety and tolerability of an injectable study drug and its effects on calcium levels in the blood and the amount of calcium passed in the urine, in adults with hypoparathyroidism, when given once a day versus twice a day. The long-term goal of this therapy is to improve calcium control and potentially to reduce daily doses and the frequency of use of calcium and vitamin D supplements.

See if you may qualify

Each person will be evaluated to determine his or her eligibility to participate in the study. Those who qualify will receive the study drug and study-related medical care at no cost to them. Participants may also be reimbursed for travel expenses.